Zhuzhou Qianjin Pharmaceutical (600479.SH): Progesterone soft capsule, Linagliptin tablets obtained drug registration certificate.

Zhuzhou Qianjin Pharmaceutical (600479.SH) announced recently that the company and its wholly-owned subsidiary, Hunan Qianjin Xielijiao Pharmaceutical Co., Ltd. (hereinafter referred to as "Qianjin Xielijiao Pharmaceutical"), have each received the "Drug Registration Certificate" for progesterone soft capsules (0.1g, 0.2g) and linagliptin tablets issued by the National Medical Products Administration. The progesterone soft capsules, available in 0.1g and 0.2g specifications, are reference drugs including the original imported progesterone soft capsules with the brand name Utrogestan. This reference drug was developed by Besins Healthcare in Belgium, and the 0.1g specification was approved for market in Belgium in September 1981, while the 0.2g specification was approved in Belgium in January 2006. The 0.1g specification of Utrogestan was imported into China in October 1992, and the 0.2g specification was imported in May 2013. The indications for progesterone soft capsules include functional disorders caused by luteal deficiency: menstrual disorders caused by ovulatory dysfunction; dysmenorrhea and premenstrual syndrome; bleeding (caused by fibroids, etc.); premenopausal disorders; menopause (used for supplemental estrogen therapy). This product also aids in pregnancy. Besins Healthcare's progesterone soft capsules are marketed in multiple countries, including the Netherlands, France, the UK, Switzerland, and Spain. According to Minet data, the total sales volume of progesterone soft capsules in the domestic medical and retail markets is expected to reach 344 million yuan by 2025. Linagliptin tablets are a new type of oral antidiabetic drug jointly developed by Boehringer Ingelheim and Eli Lilly, belonging to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. DPP-4 can degrade glucose-dependent insulinotropic peptide-1 (GLP1) and glucose-dependent insulinotropic peptide (GIP). Linagliptin inhibits the activity of DPP4, reduces the degradation of intestinal insulinotropic peptides, increases their concentration, stimulates insulin release in a glucose-dependent manner, and thus reduces the blood glucose concentration of type 2 diabetes patients before and after meals. This drug is used as an adjunct to diet control and exercise to improve blood sugar control in patients with type 2 diabetes. According to Minet data, the total sales volume of linagliptin tablets in the domestic medical and retail markets is expected to reach 1.137 billion yuan by 2025.